Supplemental Figure 1 Auranofin BSO Zn-BG ABC D carfilzomib Supplemental Table1: Characteristics of CLL patients in this study; * status unknown Supplemental Figure 2 CLL-7607 CLL-7620 Control 1.0 M AF, 24 h AB C Supplemental Figure 3 NLCCLL p=nsp= R e l a t i v e c h a n g e i n v i a b i l i t y 1.0 M AF, 24 h V i a b i l i t y ( % ) CLL, p=.005 NLC, p=ns 1.0 M AF Control Before treatmentAfter treatment Mouse no x x 10 6 Mouse no x x 10 5 Mouse no x x 10 6 Mouse no x x 10 6 Mouse no x x 10 6 Leukemia cell burden Supplemental Table 2: Leukemia cell burden for individual TCL-1 mice pre- and post-treatment with 2 weeks of auranofin. Affy_IDGeneFold Expression Change _atHMOX _atGCLM _atDNAJA _s_atHSPB _s_atTXN _atMAFF _s_atHSP90AA _atDNAJB _s_atE2F _s_atSQSTM _s_atGADD45B _atUBB _s_atHSP90AB _s_atNQO _s_atMAFG _atGSR _atPRDX _s_atCDKN1A _atKEAP _atNFE2L _atSOD _atTLR _atTGFBR _atSMAD _atBACH _atTNIP _atFLT _atSYK _atTAP _atTIFA _atTNFRSF1B _atRGS _atIL2RA _s_atMAP2K _s_atPDE4DIP _x_atNCF1C _s_atAKR7A _atPSMB _s_atPSMB Supplemental Table 3: Gene expression changes of the 39 most up and downregulated genes in primary CLL cells following treatment with 1.0 M of AF for 8 hours Network ID Associated Network FunctionsScore 1 Protein Degradation, Protein Synthesis, Cellular Movement 41 2 Cellular Compromise, Cellular Function and Maintenance, Drug Metabolism 40 3 Free Radical Scavenging, Cellular Compromise, Molecular Transport 34 4 Endocrine System Disorders, Gastrointestinal Disease, Immunological Disease 29 5 Lipid Metabolism, Small Molecule Biochemistry, Infectious Disease 28 Supplemental Table 4: Ingenuity pathway analysis of the top 5 perturbed networks in Primary CLL cells treated with 1 M of AF Supplemental Figure 4 Zn-BG (M) + AF (nM)FACI MEC-1 A. Zn-BG (M) + AF (nM) FACI Primary CLL B. Supplemental Figure 5 C.D. BSO (M) + AF (nM)FACI MEC-1 BSO (M) + AF (nM)FACI Primary CLL Supplemental Figure 6 -Actin CL. CASP3 MEC mM NAC, 8 h 500 M H 2 O 2, 8 h GRP78 Nrf2 CHOP A